title: [Measurement of coronary flow reserve using adenosine 5'-triphosphate in dogs].
abstract: Adenosine 5'-triphospate (ATP) was compared with adenosine and papaverine for the measurement of coronary flow reserve in 12 anesthetized dogs. Intracoronary bolus injection of ATP (1 ml, 1-500 microM) produced a dose dependent increase in the blood flow of the left anterior descending artery, which attained the plateau at the dose of 100 microM. The ratio of peak to resting coronary flow volume (coronary flow reserve) with 100 microM of ATP (3.5 +/- 0.5) was similar to that with 200 microM of adenosine (4.0 +/- 0.7) and 50 mM of papaverine (3.7 +/- 0.8). Hemodynamic variables did not change after administration of each drug, except left ventricular regional wall motion abnormality during papaverine injection. The coronary flow reserve as measured after intracoronary ATP administration (100 microM) decreased as the grade of stenosis of the left anterior descending artery progressed. In addition, the flow reserve was similar to that of adenosine or papaverine administration at each stenosis grade. Intravenous administration of ATP (1,000 micrograms/min) caused a similar increase in coronary blood flow as intracoronary ATP injection (100 microM). However, premedication with 8-phenyltheophylline, an adenosine receptor blocker, significantly suppressed the coronary dilatory effect of intravenous ATP and intracoronary adenosine but not the effect of intracoronary ATP. These results indicate that intracoronary ATP is useful for measuring coronary flow reserve and that its coronary dilatory effect is not mediated by metabolysis to adenosine.
authors.affiliation: Second Department of Internal Medicine, Kyoto Prefectural University of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Kohno
authors.forename: H
authors.initials: H
authors.lastname: Yamada
authors.forename: A
authors.initials: A
authors.lastname: Azuma
authors.forename: M
authors.initials: M
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Yagi
authors.forename: K
authors.initials: K
authors.lastname: Kawata
authors.forename: H
authors.initials: H
authors.lastname: Tatsukawa
authors.forename: H
authors.initials: H
authors.lastname: Sugihara
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects*; D003331:Coronary Vessels; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006439:Hemodynamics / Q000187:drug effects; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D010208:Papaverine / Q000008:administration & dosage / Q000494:pharmacology; D058915:Purinergic P1 Receptor Antagonists; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D058915:Purinergic P1 Receptor Antagonists; D014665:Vasodilator Agents; D000255:Adenosine Triphosphate; D013806:Theophylline; D010208:Papaverine; C028322:8-phenyltheophylline; D000241:Adenosine